Related Experiment Videos
[Fungal infections -- always dangerous for immunosuppressed patients (author's transl)]
Abstract:
Four renal transplant recipients, treated with the immunosuppressive combination of azathioprine-prednisolone, developed organ or systemic mycoses caused by Candida albicans and, in one case, additionally by Trichophyton rubrum. Ketoconazole, a new wide-spectrum antimycotic drug, was successfully used in the treatment of the fungal infections in these patients. The oral route of administration, good tolerance and excellent results are good recommendations for this drug.
Insights
New antifungal ketoconazole effectively treated fungal infections in four kidney transplant patients. The drug, administered orally, showed good tolerance and excellent results in managing mycoses caused by Candida albicans.
Area of Science:
- Medical Mycology
- Transplantation Immunology
Background:
- Renal transplant recipients often require immunosuppressive therapy, increasing susceptibility to opportunistic infections.
- Azathioprine-prednisolone is a common immunosuppressive regimen used post-transplantation.
Observation:
- Four patients undergoing immunosuppressive therapy developed systemic or organ mycoses.
- Infections were primarily caused by Candida albicans, with one case also involving Trichophyton rubrum.
Findings:
- Ketoconazole, a novel broad-spectrum antimycotic agent, was administered orally to treat these fungal infections.
- Successful treatment outcomes were observed in all four patients.
- The drug demonstrated good tolerance and efficacy.
Implications:
- Ketoconazole presents a viable and effective treatment option for fungal infections in immunosuppressed transplant patients.
- Oral administration and favorable tolerance profile make ketoconazole a recommended therapeutic choice.
- Further research into antifungal strategies for transplant recipients is warranted.